Skip to content

Study · Animal study (in vivo) · rat · 2010

5 results

NNZ-2591, a novel diketopiperazine, prevented scopolamine-induced acute memory impairment in the adult rat.

Guan J, Zhang R, Dale-Gandar L, Hodgkinson S, Vickers MH

Behavioural brain research25 Feb 2010Cited by 21 (Europe PMC)

PMID20188767 (opens in a new tab)DOI10.1016/j.bbr.2010.02.039 (opens in a new tab)PepBankPUB-20188767
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In scopolamine-treated rats, NNZ‑2591 did not reverse the spatial learning and memory deficit versus water.

    In plain wordsIn scopolamine-treated rats, NNZ‑2591 did not reverse the learning and memory deficit versus water.

    Peptide
    NNZ-2591
    Outcome
    No significant changeSpatial learning and memory deficit
    Study

    ratsn: not reported in source

    adult male Wistar rats with scopolamine-induced amnesia
    Comparator
    Scopolamine and water
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    30 mg/kg · oral gavageAs given in this study (rats).

    Source sentences

    Summary
    NNZ-2591 did not reverse this deficit,
    3 context sentences
    Summary · context
    Scopolamine impaired spatial learning and memory compared to saline treated group, particularly in the day 1 acquisition trial.
    Summary · context
    Adult male Wistar rats were assigned to four groups: saline/water; saline/NNZ-2591; scopolamine/water and scopolamine/NNZ-2591.
    Summary · context
    Either NNZ-2591 (30 mg/kg) or water was administered orally (gavages) 10 min after the injection.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In scopolamine-treated rats, NNZ‑2591 significantly improved memory retention versus water, increasing time in the correct quadrant.

    In plain wordsIn scopolamine-treated rats, NNZ‑2591 improved memory retention versus water.

    Peptide
    NNZ-2591
    Outcome
    IncreaseMemory retention
    Study

    ratsn: not reported in source

    adult male Wistar rats with scopolamine-induced amnesia
    Comparator
    Scopolamine and water
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    30 mg/kg · oral gavageAs given in this study (rats).

    Source sentences

    Summary
    NNZ-2591 did not reverse this deficit, however it significantly improved memory retention by showing more time spent in the correct quadrant.
    2 context sentences
    Summary · context
    Adult male Wistar rats were assigned to four groups: saline/water; saline/NNZ-2591; scopolamine/water and scopolamine/NNZ-2591.
    Summary · context
    Either NNZ-2591 (30 mg/kg) or water was administered orally (gavages) 10 min after the injection.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In rats, NNZ‑2591 counteracted the scopolamine-induced increase in striatal choline-acetyltransferase-positive neurons versus water.

    In plain wordsIn rats, NNZ‑2591 counteracted the scopolamine-induced increase in striatal choline-acetyltransferase-positive neurons versus water.

    Peptide
    NNZ-2591
    Outcome
    DecreaseStriatal choline-acetyltransferase-positive neurons
    Study

    ratsn: not reported in source

    adult male Wistar rats with scopolamine-induced amnesia
    Comparator
    Scopolamine and water
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    30 mg/kg · oral gavageAs given in this study (rats).

    Source sentences

    Summary
    NNZ-2591 also counteracted the scopolamine-induced up-regulation of choline-acetyltransferase positive neurons in the striatum and similarly counteracted the increased synaptophysin density in the hippocampus.
    2 context sentences
    Summary · context
    Adult male Wistar rats were assigned to four groups: saline/water; saline/NNZ-2591; scopolamine/water and scopolamine/NNZ-2591.
    Summary · context
    Either NNZ-2591 (30 mg/kg) or water was administered orally (gavages) 10 min after the injection.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In rats, NNZ‑2591 counteracted the scopolamine-induced increase in hippocampal synaptophysin density versus water.

    In plain wordsIn rats, NNZ‑2591 counteracted the scopolamine-induced increase in hippocampal synaptophysin density versus water.

    Peptide
    NNZ-2591
    Outcome
    DecreaseHippocampal synaptophysin density
    Study

    ratsn: not reported in source

    adult male Wistar rats with scopolamine-induced amnesia
    Comparator
    Scopolamine and water
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    30 mg/kg · oral gavageAs given in this study (rats).

    Source sentences

    Summary
    NNZ-2591 also counteracted the scopolamine-induced up-regulation of choline-acetyltransferase positive neurons in the striatum and similarly counteracted the increased synaptophysin density in the hippocampus.
    2 context sentences
    Summary · context
    Adult male Wistar rats were assigned to four groups: saline/water; saline/NNZ-2591; scopolamine/water and scopolamine/NNZ-2591.
    Summary · context
    Either NNZ-2591 (30 mg/kg) or water was administered orally (gavages) 10 min after the injection.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In rats, NNZ‑2591 showed a scopolamine-independent antagonistic effect on muscarinic M2 acetylcholine receptors.

    In plain wordsIn rats, NNZ‑2591 blocked muscarinic M2 acetylcholine receptors independently of scopolamine.

    Peptide
    NNZ-2591
    Outcome
    Not applicableMuscarinic M2 receptor antagonism
    Study

    ratsn: not reported in source

    adult male Wistar rats
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    30 mg/kg · oral gavageAs given in this study (rats).

    Source sentences

    Summary
    Furthermore, a scopolamine-independent antagonistic effect on muscarinic M2 acetylcholine receptors was found after NNZ-2591 treatment, supporting its modulation of acetylcholine neurotransmission.
    2 context sentences
    Summary · context
    Adult male Wistar rats were assigned to four groups: saline/water; saline/NNZ-2591; scopolamine/water and scopolamine/NNZ-2591.
    Summary · context
    Either NNZ-2591 (30 mg/kg) or water was administered orally (gavages) 10 min after the injection.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.